证券代码：300199 证券简称：翰宇药业 公告编号：2025-043 披露的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳翰宇药业股份有限公司于 2025 年 9 月 25 日召开了第六届董事会第七次 会议和第六届监事会第四次会议，会议审议通过了关于 2025 年度向特定对象发 行 A 股股票的相关议案。《深圳翰宇药业股份有限公司 2025 年度向特定对象发 行 A 股股票预案》（以下简称"预案"）及相关公告已于同日在中国证监会指 定的创业板信息披露网站巨潮资讯网（http://www.cninfo.com.cn）上披露，敬请 广大投资者注意查阅。 该预案披露事项不代表审核机关对于本次向特定对象发行股票相关事项的 实质性判断、确认或批准，预案所述本次发行股票相关事项的生效和完成尚需获 得深圳证券交易所审核通过和中国证券监督管理委员会的同意注册，敬请广大投 资者注意投资风险。 特此公告。 深圳翰宇药业股份有限公司董事会 2025 年 9 月 26 日 深圳翰宇药业股份有限公司 关于 2025 年度向特定对象发行股票预案 ...

证券代码：300199 证券简称：翰宇药业 深圳翰宇药业股份有限公司 2025 年度向特定对象发行 A 股股票 预案 二〇二五年九月 1 深圳翰宇药业股份有限公司 2025 年度向特定对象发行 A 股股票预案 公司声明 1、公司及董事会全体成员保证本预案内容真实、准确、完整，并确认不存 在虚假记载、误导性陈述或重大遗漏，对预案的真实性、准确性、完整性承担个 别和连带的法律责任。 2、本次发行预案（以下简称"本预案"）按照《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司证券发行注册管理办法》等法律、法规及规范 性文件的要求编制。 3、本次向特定对象发行 A 股股票完成后，公司经营与收益的变化由公司自 行负责；因本次向特定对象发行 A 股股票引致的投资风险，由投资者自行负责。 4、本预案是公司董事会对本次向特定对象发行 A 股股票的说明，任何与之 相反的声明均属不实陈述。 5、投资者如有任何疑问，应咨询自己的股票经纪人、律师、专业会计师或 其他专业顾问。 6、本预案所述事项并不代表审批机关对于本次向特定对象发行 A 股股票相 关事项的实质性判断、确认或批准，本预案所述本次发行相关事项的生效和完成 尚待 ...

Core Viewpoint - The company announced the approval of a plan to issue A-shares to specific investors during a board meeting scheduled for September 25, 2025, pending regulatory approvals [1] Group 1 - The company will hold a board and supervisory board meeting on September 25, 2025, to review the proposal for the issuance of A-shares [1] - The relevant proposal and announcement have been disclosed on the Giant Tide Information Network [1] - The issuance of shares is subject to approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission [1]

深圳翰宇药业股份有限公司第六届董事会 第二次独立董事专门会议审核意见 根据《中华人民共和国公司法》（以下简称《公司法》）《中华人民共和国 证券法》（以下简称《证券法》）《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相 关法律、法规及规范性文件的规定以及《公司章程》《独立董事工作细则》的有 关规定，我们作为公司的独立董事，基于独立判断的立场，本着实事求是的原则， 召开了第六届董事会第二次独立董事专门会议。 本次会议应出席独立董事 3 人，实际出席独立董事 3 人，独立董事认真审阅 了议案内容，在保证所获得的资料真实、准确、完整的基础上，本着勤勉尽责的 态度，基于独立客观的原则并发表审核意见如下： 一、《关于公司符合向特定对象发行 A 股股票条件的议案》的审核意见 经审核，我们认为：根据《公司法》《证券法》《上市公司证券发行注册管 理办法》（以下简称《注册管理办法》）等相关法律、法规及规范性文件的规定， 对照上市公司向特定对象发行股票（以下简称"本次发行"）相关资格、条件和 要求，经对公司的实际情况进行逐项自查，我们认为公司符合上述相关法律、法 ...

Group 1 - The cell immunotherapy sector experienced a decline of 2.75%, ranking among the top losers in the concept sector, with ST Zhongzhu hitting the daily limit down [1] - Major stocks within the cell immunotherapy sector that saw significant declines include Zhaoyan New Drug, Jimin Health, and Boteng Co., with respective drops of 6.04%, 5.45%, and 5.34% [1][2] - The sector faced a net outflow of 1.61 billion yuan from main funds, with 48 stocks experiencing outflows, and six stocks seeing outflows exceeding 100 million yuan, led by Hengrui Medicine with a net outflow of 293 million yuan [2] Group 2 - The top gainers in today's concept sectors included the SMIC concept with a rise of 1.22% and the National Big Fund holding with an increase of 1.08% [2] - The main inflows were observed in stocks such as Betta Pharmaceuticals, Chutian Technology, and Rongchang Bio, with net inflows of 35.97 million yuan, 21.30 million yuan, and 14.08 million yuan respectively [4] - The overall market sentiment reflected a mixed performance across various sectors, with notable declines in the Huawei Pangu and MLOps concepts, down 3.69% and 3.31% respectively [2]

Group 1 - On September 19, Hanyu Pharmaceutical experienced a decline of 2.74% with a trading volume of 1.232 billion yuan [1] - The financing data on the same day showed a financing purchase amount of 120 million yuan and a financing repayment of 159 million yuan, resulting in a net financing outflow of 38.83 million yuan [1] - As of September 19, the total balance of margin trading for Hanyu Pharmaceutical was 1.473 billion yuan, accounting for 6.91% of its circulating market value, which is above the 80th percentile of the past year [1] Group 2 - As of June 30, the number of shareholders for Hanyu Pharmaceutical reached 63,000, an increase of 9.95% compared to the previous period [2] - The company reported a revenue of 549 million yuan for the first half of 2025, representing a year-on-year growth of 114.86%, and a net profit attributable to shareholders of 145 million yuan, a significant increase of 1504.30% [2] - Since its A-share listing, Hanyu Pharmaceutical has distributed a total of 417 million yuan in dividends, with no dividends paid in the last three years [2]

Core Insights - The 10th Huawei Connect Conference was held in Shanghai from September 18 to 20, focusing on the future development trends and solutions in the pharmaceutical industry [1] - Hanyu Pharmaceutical, a leader in peptide drug research and production, launched a peptide AI process optimization assistant in collaboration with Huawei Cloud, marking a significant milestone in their partnership [1][2] Group 1: Collaboration and Technology - Hanyu Pharmaceutical and Huawei Cloud signed a comprehensive cooperation agreement on April 27, 2023, focusing on drug research model applications, digital platform construction, data governance, and AI talent cultivation [1] - The newly launched AI process optimization assistant utilizes over 100,000 historical process data accumulated by Hanyu Pharmaceutical, creating an intelligent private database that integrates with global authoritative chemical databases [2] Group 2: Performance Metrics - The AI process optimization assistant has demonstrated breakthrough results in various research and production stages, showcasing the significant application value of large model technology in pharmaceutical research [2] - Quantitative data indicates that the application of the large model will shorten research and development cycles by 45%, reduce trial and error costs by over 20%, enhance process parameter decision efficiency by 90%, and improve batch qualification rates by 22% [2] Group 3: Industry Alignment and Future Directions - The collaboration aligns with national policies promoting digital transformation in the pharmaceutical industry, as outlined in the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)" [3] - Hanyu Pharmaceutical's Vice President emphasized the importance of this collaboration as a practical example of the pharmaceutical industry embracing "new quality productivity" and plans to deepen cooperation while ensuring data security and compliance [3]

Core Insights - On September 9, Hanyu Pharmaceutical experienced a decline of 1.68% with a trading volume of 1.406 billion yuan [1] - As of September 9, the total margin balance for Hanyu Pharmaceutical was 1.519 billion yuan, accounting for 7.16% of its circulating market value, indicating a high level of margin financing [1] - For the first half of 2025, Hanyu Pharmaceutical reported a revenue of 549 million yuan, representing a year-on-year growth of 114.86%, and a net profit of 145 million yuan, showing a significant increase of 1504.30% [2] Financing and Margin Data - On September 9, Hanyu Pharmaceutical had a margin buy-in of 113 million yuan and a margin repayment of 116 million yuan, resulting in a net margin buy of -2.89 million yuan [1] - The margin balance of 1.519 billion yuan is above the 90th percentile of the past year, indicating a high level of borrowing activity [1] - The short-selling data on September 9 showed no shares were sold or repaid, with a short-selling balance of 0, placing it in the 70th percentile of the past year [1] Shareholder and Dividend Information - As of June 30, the number of shareholders for Hanyu Pharmaceutical increased by 9.95% to 63,000, while the average circulating shares per person decreased by 3.98% to 11,841 shares [2] - Since its A-share listing, Hanyu Pharmaceutical has distributed a total of 417 million yuan in dividends, with no dividends paid in the last three years [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 7.6817 million shares, a decrease of 386,400 shares compared to the previous period [2]

Company Overview - Hanyu Pharmaceutical Co., Ltd. is located in Longhua District, Shenzhen, Guangdong Province, and was established on April 2, 2003. The company was listed on April 7, 2011. Its main business involves chemical pharmaceuticals and medical devices, with 100% of its revenue coming from the pharmaceutical manufacturing industry [1]. Stock Performance - As of September 3, Hanyu Pharmaceutical's stock price decreased by 2.02%, trading at 26.16 CNY per share, with a total market capitalization of 23.106 billion CNY. The stock has increased by 102.95% year-to-date, with a 0.19% increase over the last five trading days, an 11.79% increase over the last 20 days, and a 53.88% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on August 4, where it recorded a net purchase of 545 million CNY [1]. Financial Performance - For the first half of 2025, Hanyu Pharmaceutical achieved a revenue of 549 million CNY, representing a year-on-year growth of 114.86%. The net profit attributable to the parent company was 145 million CNY, showing a significant year-on-year increase of 1504.30% [2]. - The company has distributed a total of 417 million CNY in dividends since its A-share listing, with no dividends distributed in the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 9.95% to 63,000, with an average of 11,841 circulating shares per person, a decrease of 3.98% from the previous period [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 7.6817 million shares, which is a decrease of 386,400 shares compared to the previous period [3].

Core Viewpoint - The pharmaceutical industry, particularly biotech companies, is expected to experience a significant market upturn from late 2024 to mid-2025, supported by global market growth and strong performance in the Chinese pharmaceutical market [1][3]. Market Trends - The rapid growth of BD (business development) activities, the reopening of the Sci-Tech Innovation Board, and the performance of Hong Kong's secondary market indicate that the industry is entering a valuation recovery phase [1]. - Despite some biotech companies experiencing substantial stock price increases, many investors have not yet recouped their costs due to the timing of investments [1][2]. Investment Landscape - High-quality companies that address clinical needs are more likely to survive market downturns, while many biotech firms have failed to navigate the recent market challenges [2]. - The current secondary market appears prosperous, but from the perspective of primary market entrepreneurs, it is still in a winter phase [2]. Challenges and Opportunities - The difficulty of listing biotech companies in both China and the U.S. has led to diversified financing channels, with investors focusing on asset quality and clinical research data [3]. - The demand for high-quality, cost-effective products is increasing due to global aging populations and limited healthcare funding [4]. Global Positioning - Chinese innovators have significantly narrowed the development gap with the U.S., with a reported 38% year-on-year increase in overseas licensing deals, totaling $60.8 billion in the first half of 2025 [5][6]. - The shift from generic to original drug development in China is expected to have a profound impact on the global pharmaceutical market [6]. R&D Efficiency - China leads globally in R&D efficiency from "1 to 10," while the U.S. remains dominant in "0 to 1" development [6]. - The ability to produce unique products, particularly in ADC (antibody-drug conjugates), is attributed to China's strong engineering capabilities [9]. Future Growth Areas - The most promising research areas for capital investment are in immunology and metabolic/cardiovascular fields [7]. - The market is witnessing a divide, with leading companies leveraging innovation and digital empowerment, while smaller firms face greater pressure due to homogenized competition [6][10]. Strategic Directions - Companies are encouraged to explore new financing models, such as RWA (Real World Asset) tokenization, to better access markets [11]. - The focus on license-out opportunities and the promotion of inclusive healthcare are critical strategies for pharmaceutical companies [12].